Acorda Therapeutics Presents Data from its Phase 3 Study of ...
Genetic Engineering News (press release) - New Rochelle,NY,USA
Acorda Therapeutics, Inc.(R) (Nasdaq: ACOR) today presented data from a Phase 3 clinical trial of Fampridine-SR in people with multiple sclerosis (MS) at ...
electrical signals to pass through areas of damage.

Webcast

Acorda will hold a webcast this evening at 7 p.m. Eastern Time. Study data will be presented and members of the Acorda management team will be available for a question and answer session. To access the webcast please log on to http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=194451 &eventID=1529938 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)